Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Merck | Contract Pharma

What are you searching for?

Sign in
Financial News

Financial Report: Merck

Pharmaceutical sales up 9% in the quarter

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Merck
1Q Revenues: $10.0 billion (+6%)
1Q Earnings: $3.6 billion (+14%)
Comments: Pharmaceutical sales were $8.9 billion in the quarter, up 9% primarily driven by growth in oncology, diabetes, partially offset by lower sales in virology and the ongoing impacts of the loss of market exclusivity for several products. Keytruda sales were up 151% to $1.5 billion in the quarter. Januvia sales were up 7% to $1.4 billion. Gardasil sales were up 24% to $660 million. PROQUAD, M-M-R II and VARIVAX sales were $392 million, up 10%. Zetia/Vytorin sales continued to decline, down 18% to $471 million. Isentress sales were down 8% to $281 million. Simponi sales were up 26% to $231 million. Animal Health sales were $1.1 billion, up 13%.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters